Author:
Sleijfer Stefan,Verweij Jaap
Publisher
Springer Science and Business Media LLC
Reference7 articles.
1. Eijsden, P. Fate of new cancer drug is uncertain in Netherlands, as institute deems it too costly. BMJ 351, h6778 (2015).
2. van Harten, W. H., Wind, A., de Paoli, P., Saghatchian, M. & Oberst, S. Actual costs of cancer drugs in 15 European countries. Lancet Oncol. 17, 18–20 (2016).
3. Beije, N., Jager, A. & Sleijfer, S. Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment? Cancer Treat. Rev. 41, 144–150 (2015).
4. Sickinger, M. T. et al. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma. Cochrane Database Syst. Rev. 1, CD010533 (2015).
5. Davar, D., Socinski, M. A., Dacic, S. & Burns, T. F. Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. Exp. Hematol. Oncol. 4, 34 (2015).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献